Last reviewed · How we verify
Amiloride 20 mg — Competitive Intelligence Brief
phase 3
Small molecule
Live · refreshed every 30 min
Target snapshot
Amiloride 20 mg (Amiloride 20 mg) — Hospital de Clinicas de Porto Alegre.
Comparator set
| Drug | Generic | Sponsor | Phase | Class | Target | Approval / PDUFA |
|---|---|---|---|---|---|---|
| Amiloride 20 mg TARGET | Amiloride 20 mg | Hospital de Clinicas de Porto Alegre | phase 3 |
Recent regulatory actions (last 90 days)
Upcoming PDUFA dates (next 180 days)
Patent timeline (forward window)
Sponsor landscape
Subscribe to ongoing alerts
Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:
- Amiloride 20 mg CI watch — RSS
- Amiloride 20 mg CI watch — Atom
- Amiloride 20 mg CI watch — JSON
- Amiloride 20 mg alone — RSS
Cite this brief
Drug Landscape (2026). Amiloride 20 mg — Competitive Intelligence Brief. https://druglandscape.com/ci/amiloride-20-mg. Accessed 2026-06-10.
Build your own brief
Pick any drug + add comparators:
https://druglandscape.com/ci/{slug}— auto-detected competitorshttps://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3— explicit comparators- Brand names auto-resolve:
/ci/keytruda→ 301 →/ci/pembrolizumab
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing